Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combivent Respimat versus Combivent Inhalation Aerosol and ipratropium Respimat in adults with COPD
2006-002694-52Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2006
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, double-blind trial of Combivent and ipratropium bromide in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Bronchodilator efficacy and Safety. Started Oct 2006; status: completed.
02
Drugs
Combiventipratropium bromide
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2006-002694-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002694-52.